Evidence map›Paper›PMID 29167335›Full record

ArticleJournal of virology2018

β-d-

Nadya Urakova, Valeriya Kuznetsova, David K Crossman, Arpine Sokratian, David B Guthrie, Alexander A Kolykhalov, Mark A Lockwood, Michael G Natchus, Michael R Crowley, George R Painter and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 1 synthesis or guideline pooled it, 204 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Nadya Urakova *Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Valeriya Kuznetsova *Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
David K CrossmanHeflin Center for Genomic Science, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Arpine SokratianDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
David B GuthrieEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Alexander A KolykhalovEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Mark A LockwoodEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Michael G NatchusEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Michael R CrowleyHeflin Center for Genomic Science, University of Alabama at Birmingham, Birmingham, Alabama, USA.
George R PainterEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Elena I FrolovaDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA efrolova@uab.edu ivfrolov@uab.edu.ORCID 0000-0001-6523-9336
Ilya FrolovDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA efrolova@uab.edu ivfrolov@uab.edu.ORCID 0000-0002-8548-2517
University of Alabama at Birmingham · USEmory University · US

Funding

Alphavirus nsP3 protein: roles of intrinsically disordered region in virus replication and pathogenesisR01AI118867 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FROLOVA, ELENA I · 2015 to 2019
$1.8M
Mechanism of alphavirus packaging: designing of pseudoinfectious virusesR01AI095449 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FROLOV, ILYA V. · 2012 to 2016
$1.8M
NIAID NIH HHS R01 AI095449NIAID NIH HHS R01 AI118867
6 · The paper itself

Abstract

Venezuelan equine encephalitis virus (VEEV) is a representative member of the New World alphaviruses. It is transmitted by mosquito vectors and causes highly debilitating disease in humans, equids, and other vertebrate hosts. Despite a continuous public health threat, very few compounds with anti-VEEV activity in cell culture and in mouse models have been identified to date, and rapid development of virus resistance to some of them has been recorded. In this study, we investigated the possibility of using a modified nucleoside analog, β-d-

Indexed as

MutationAlphavirusAnimalsAntiviral AgentsCell LineChlorocebus aethiopsCricetinaeCytidineGenome, ViralHumansRibavirinVero CellsViral LoadViral Nonstructural ProteinsAntiviral AgentsCytidineN(4)-hydroxycytidineRibavirinViral Nonstructural Proteinsalphavirusesantiviralsdrug-resistant mutantlethal mutagenesisN-hydroxycytidineRNA-dependent RNA polymeraseVenezuelan equine encephalitis virus

Identifiers

PMID29167335
PMCPMC5774879
OpenAlexW2770157223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.